SIGMA Pharma agreed to buy Orphan Australia for $130 million

Sigma said Melbourne-based Orphan would provide it with an entry into a number of high-value, high-growth specialised therapeutics from international pharmaceutical and biotechnology companies, which Orphan focuses on licensing, marketing and distributing. With double-digit revenue growth in each of the past three years, Orphan is expected to generate sales of around $40 million and earnings before interest, taxation depreciation and amortisation of around $13 million during the year to June 2008, a Sigma statement said.